Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey.
Multidrug resistant HIV-1 acquired at the time of primary infection in two patients persisted for at least 5 years with and without treatment. In each patient, only one back mutation to wild-type codon in the protease gene occurred, and that was concomitantly associated with a marked CD4 cell count decrease. In both cases, infection was caused by CCR5 viruses and no rapid clinical progression to AIDS after primary infection was observed.
Delaugerre
Constance
C
Department of Virology-EA3620, Necker Hospital, Paris, France.
Marcelin
Anne-Genevieve
AG
Soulié
Cathia
C
Chaix
Marie-Laure
ML
Katlama
Christine
C
Girard
Pierre-Marie
PM
Calvez
Vincent
V
Morand-Joubert
Laurence
L
D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D024921:Drug Resistance, Multiple, Viral / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000635:transmission* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000276:immunology*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D061466:Lopinavir; D009154:Mutation / Q000235:genetics / Q000276:immunology; D063065:Organophosphonates / Q000627:therapeutic use; D011744:Pyrimidinones / Q000627:therapeutic use; D012367:RNA, Viral / Q000032:analysis; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D000068698:Tenofovir; D019562:Viral Load
D044966:Anti-Retroviral Agents; D017320:HIV Protease Inhibitors; D063065:Organophosphonates; D011744:Pyrimidinones; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D061466:Lopinavir; D019259:Lamivudine; D000068698:Tenofovir; D000225:Adenine; D019438:Ritonavir